Multimodal Treatment of Breast Cancer Liver Metastases Based on Hepatic Resection and Microwave Coagulo-Necrotic Therapy ( MCN )

C l i n M e d International Library Citation: Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, et al. (2016) Multimodal Treatment of Breast Cancer Liver Metastases Based on Hepatic Resection and Microwave CoaguloNecrotic Therapy (MCN). Int J Cancer Clin Res 3:038 Received: December 11, 2015: Accepted: January 09, 2016: Published: January 11, 2016 Copyright: © 2016 Takami Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Takami et al. Int J Cancer Clin Res 2016, 3:038

Liver surgeons, on the other hand, are used to numerous hepatic metastases of other cancers, such as colorectal cancer.In addition, hepatic metastases, together with cerebral metastases of breast cancer, are considered to be life-threatening metastases and lifelimiting factors, and they thus constitute a highly important factor with respect to prognosis.Therefore, liver surgeons tend to consider that hepatic resection contributes to improved prognosis when anatomically feasible [4].There is thus a major gap between breast and liver surgeons' positions with respect to BCLM.
An additional point is that, at our center, favorable therapeutic results have been achieved with multiple as well as single hepatocellular carcinoma (HCC), albeit with only a small number of patients, by means of microwave coagulo-necrotic therapy (MCN) as well as resection [5].Therefore, surgical treatment has been carried out at our center, because of the probability that surgical treatment combining hepatic resection and/or MCN is useful for treating multiple BCLM.Surgery has been selected at our center for 33 patients with BCLM, the therapeutic results were evaluated, and the usefulness is reported here.

Introduction
It is only in approximately 5% of breast cancer cases that ISSN: 2378-3419 3 months, and in the event of solely intrahepatic recurrence, options such as repeated surgery, and hepatic arterial infusion were looked into.
The Kaplan-Meier method was used for calculating the survival rate, and the log-rank test was used to compare survival rates.For all statistical values, the significant difference was taken to be P < 0.05.
The hepatic metastases were metachronous in 27 subjects, and synchronous in 6.Excluding the synchronous cases, the period from breast cancer surgery to onset of hepatic metastases was 9 to 227 months (mean, 45.7 months).When the one patient with whom this period was 227 months (mean, 38.8 months), an unusually long time, was excluded.
After breast cancer surgery, adjuvant chemotherapy was carried out with 23 patients, and, among the 27 patients with metachronoushepatic metastases, with 11 patients neo-adjuvant therapy was carried out between discovery of the hepatic metastases whom multiple hepatic micro metastases, which had not been shown by diagnostic imaging immediately beforehand at a different hospital, were found.
The surgical treatments used for BCLMare hepatic resection and MCN.Of these therapies, MCN is a loco-regional treatment method that has been used for HCC since the center was opened, involving the use of microwaves under laparoscopy, with laparotomy or small thoracotomy.The surgical procedure involves making multiple punctures with microwave antennas, guided by ultrasound images, from the vicinity of the HCC and toward the center, followed by microwave oscillation, and the details have been reported previously [5].
The criteria for selecting hepatic resection and/or MCN as the surgical treatment for BCLM are as follows: (i) If the metastasis is superficial, and no more than 3 cm in diameter, or deep in the liver and no more than 2 cm in diameter, MCN is the first choice, whereas if it is in the hepatic margin, etc., resection is selected.
(ii) If small, multiple metastases are dispersed in both lobes of the liver, MCN is selected.
(iii) If there is a single metastasis 5 cm or more in diameter, or there are multiple, unevenly distributed metastases, resection is selected.
(iv) If at least one metastasis is 5 cm or more in diameter, and there are multiple metastases in both lobes of the liver, resection is carried out with the principal cancer nodules, and MCN is used for the remaining metastatic foci.
Even if extrahepatic metastases are also present, the resection/ MCN exclusion criteria are not met if favorable local control of the extrahepatic metastases is achieved by means of chemotherapy and/or radiotherapy at the time of surgical treatment of the hepatic metastases.
The protocol for clinical evaluation of the usefulness of surgical treatment for BCLM was validated and approved by our center's Institutional Review Board.The surgery was carried out after explaining to the subjects that surgery is not the standard treatment for BCLM, and that a combination of systemic chemotherapy and multimodal therapy, etc., is required, and then obtaining their informed consent for participation.In addition, after treating the hepatic metastases, treatment was continued with supplementary chemotherapy, endocrine treatment, etc., primarily by the specialist physicians who introduced the patients.During the observation period at the center, the patients visited the center once every  and surgical treatment at the center.In addition, with 30 patients supplementary adjuvant therapy was carried out after surgical treatment of the hepatic metastases.There were only 10 patients with whom only intrahepatic metastases were found during the treatment period, and with the other 23 patients one type or another of extra hepatic metastases was also found.These extrahepatic metastases were treated with supplementary systemic adjuvant therapy, with radiotherapy being used for bone metastases, and resection and other treatments being used for ovarian metastases (Table 1).
The types of surgery selected were hepatic resection monotherapy, with 11 patients; MCN monotherapy, with 14 patients; and hepatic resection and MCN, with 8 patients.Of the 22 patients treated with either MCN monotherapy or resection and MCN, 16 had multiple (i.e. 2 or more) hepatic metastases and the mean number of metastases was 7.9.In addition, with 7 patients who showed recurrence of hepatic metastases, supplementary hepatic resection or MCN was carried out once or twice, and with 3such patients, anti-cancer agents were administered by hepatic arterial infusion.
Of the 33 patients with BCLM, the cumulative survival rates after the initial surgery for the hepatic metastases were 90.8%, 60.9%, and 53.8%, respectively, after 1, 3, and 5 years (Figure 1).The mean survival time was 69.0 months.
Univariate analysis was carried out to evaluate the factors contributing to cumulative survival rates after treatment of hepatic metastases, and various factors were found not to be significant, including age at breast cancer onset, age at hepatic metastasis onset, estrogen-receptor status, progesterone-receptor status, human epidermal growth factor receptor 2 (HER2) status, timing of hepatic metastasis, number of hepatic metastases, and sizes of hepatic metastases.The only parameter shown to be a significant prognostic factor was presence or absence of extra hepatic metastases at the time of onset of hepatic metastases (P = 0.0153; Table 2) (Figure 2).With 7 of the 33 subjects, no recurrence of intrahepatic metastases was found for at least 3 years after surgical treatment of the hepatic metastases.Four of these subjects had single hepatic metastases,  hepatic metastases.Although it is of course recognized that BCLM is a systemic disease, considerable thought was given to treating hepatic metastases with drug therapy after the maximum possible volume reduction with appropriate use of MCN, a surgical technique of low invasiveness, and/or hepatic resection.And then the decision was made to carry out surgery, based primarily on MCN, for BCLM.However, possible difficulties with this treatment of BCLM that have been pointed out are that many breast cancer specialists will undoubtedly not accept this treatment, and its use is also likely to be queried at conferences, etc.
Nevertheless, the results of treatment of BCLMin the present survey show that prognoses were improved for numerous patients by means of surgical intervention.Similar findings in research at other clinical institutions have also previously been presented.For example, Pocard et al. carried out hepatic resection with 65 patients with BCLM, and found that the 3-and 4-year survival rates were 71 and 46% [8].
A second example is the study by Elias et al., who reported the 5-year survival and 5-year non-recurrence rates, with 44 BCLM patients, to be 34 and 22%, respectively [9].A third example is the study by Adam et al., who found hepatic resection to be feasible with 85 of 108 (75%) BCLM patients, and reported the 5-year survival rate to be 37% [10].Finally, Adam et al. also analyzed 454 BCLM patients, at 41 French clinical institutions, and showed the 5-year survival rate to be 41%, with BCLM patients being included in a favorable-prognosis group, together with kidney and ovary cancer hepatic metastasis patients, and in contrast with stomach cancer hepatic metastasis patients [4].and these were treated by hepatic resection.The other 3subjects had multiple metastases (range, 5-17), and with two of these the treatment was MCN monotherapy, whereas with the other subject it was hepatic resection and MCN (Table 3).

Discussion
In comparison with breast cancer metastases in bone, lungs, etc., the survival time with hepatic metastases is very short, at 13 to 14.5 months, and, in common with cerebral metastases, hepatic metastases are therefore considered to be life threatening metastases, and to constitute a life limiting factor.They are thought to constitute an important factor affecting prognosis [1][2][3].
Breast cancer treatment methods have been hormone therapy, anti-HER2therapy, and chemotherapy, and marked improvements in response rate have been achieved using multi-drug chemotherapy.However, as the mean survival time is still only 25 to 29 months, and the 5-year survival rate is only 12.1%, the improvements in response rate cannot be said to be clearly reflected in the survival time [6,7].
In this context, we have come to consider whether it would be possible, with BCLM also, to improve treatment outcomes by surgical intervention, similar to that used with colorectal cancer hepatic metastases.At the same time, we are quite often asked by physicians whether MCN could not be used among patients suffering recurrence after breast cancer surgery, chemotherapy shows some but limited efficacy against bone and lung metastases, but no efficacy against The favorable treatment outcome that we showed, a 5-year survival rate of 53.0%, was not solely due to hepatic resection, but also due to expansion of the indication of surgical treatment of multiple hepatic metastasis patients, together with energetic, concomitant application of MCN.We has previously reported that MCN has the capacity for local control of HCC, being at least the equal of hepatic resection in this respect [1], and it is considered that, for hepatic metastases also, ablation of individual metastases using microwaves offers the potential for local control of even multiple metastases to a degree at least equal to hepatic resection.However, it is recognized that surgical treatment is volume reduction surgery, and an approach involving supplementary use of postoperative adjuvant chemotherapy is therefore preferable.Of the 33 subjects in the present research, 30 were supplementary treated with systemic chemotherapy, endocrine therapy, and/or moleculartargeted agents.Pocard et al. have proposed that, as surgical techniques, adjuvant surgery and surgical mass reduction should be used as aspects of multimodal treatment of breast cancer.In addition, Bathe et al. have presented an approach termed "cytoreductive strategy" [11].Finally, Caralt et al. have presented an approach with a similar basis, but involving surgical intervention, termed" oncosurgical treatment" [12].
Once surgical treatment of BCLM has been judged to be feasible, this intervention should be carried out as soon as possible.We reported here the case of the 2 patients mentioned above with whom experimental laparotomy was carried out.Only 2 or 3 hepatic metastases were found on diagnostic images at that time.Although these patients had previously been administered chemotherapy and shown complete response, the patients experienced recurrence (repeated twice or 3 times), and it was therefore judged that control could not be achieved with chemotherapy, so the patients were referred to our department.When laparotomy was carried out with these patients, numerous sites of lymphatic infiltration were found in the micro-lymph-vessels of the liver surface.The suggested reason for this is that there is a fine lymph vessel network within the liver, and, even if BCLMare formed by transfer in the blood, the metastatic pattern of the original breast cancer, that is, the metastatic pattern mediated by the lymphatic system, is formed gradually during repetition of chemotherapy.On the basis of experience with these 2 patients, it is considered that surgical intervention for BCLM should probably be carried out before chemotherapy, if surgery is judged to be feasible.Similarly, Abbott et al. emphasized that it is important for chemotherapy to be effective before hepatic metastasis, and that the timing of chemotherapy before disease progression is thus important [13].
Among various factors, those that contribute to prognosis were evaluated.It has previously been reported that significant prognostic factors include age, hormone-receptor status, number of metastases, presence/absence of metachronoushepatic metastases, and R0 resection [14][15][16].However, in the present research the only significant prognostic factor found was presence/absence of extra hepatic metastases before surgical treatment of hepatic metastases.The number of hepatic metastases, and the diameters of metastatic tumors were not found to affect survival, and it is therefore considered that, even in the case of patients with multiple hepatic metastases, more serious attention should be given to the option of surgical treatment, especially in the case of patients showing no extra hepatic metastases.
In summary, it is considered that the policy relating to BCLM should involve evaluating the efficacy of surgery, rather than sticking rigidly to systemic treatment.

Conclusions
In treating BCLM, favorable results were achieved with multimodal treatment, involving maximal volume reduction surgery by means of hepatic resection and MCN, and also postoperative adjuvant chemotherapy.MCN was particularly useful for treating multiple hepatic metastases.

Figure 1 :
Figure 1: Overall survival after initial treatment for the liver metastases

Figure 2 :
Figure 2: Overall survival after initial treatment for the liver metastases based on status of the presence/absence of extra hepatic metastases at or before surgical treatment of hepatic metastases.

Table 1 :
Characteristics of 33 patients with BCLM

Table 2 :
Univariate analysis of patient's characteristics for overall survival

Table 3 :
Cases with no recurrence in the liver for more than 3years after initial treatment for liver metastases Takami et al.Int J Cancer Clin Res 2016, 3:038